Astellas Provides Update on Zolbetuximab Biologics License Application in U.S. | Antibodies

Retrieved on: 2024-01-09 15:19:16

Tags for this article:

Food and Drug Administration

Astellas Pharma

Mitsubishi UFJ Financial Group

Monoclonal antibodies

Zolbetuximab

CLDN18

Prescription Drug User Fee Act

Biologics license application

u.s. food and drug administration

Astellas Pharma Inc.

Click the tags to see associated articles and topics

Astellas Provides Update on Zolbetuximab Biologics License Application in U.S. | Antibodies. View article details on HISWAI: https://pipelinereview.com/index.php/2024010985195/Antibodies/Astellas-Provides-Update-on-Zolbetuximab-Biologics-License-Application-in-U.S.html

Excerpt

Zolbetuximab is an investigational, first-in-class chimeric IgG1 monoclonal antibody (mAb) that targets and binds to claudin 18.2 (CLDN18.2), a ...

Article found on: pipelinereview.com

View Original Article